These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30665922)

  • 21. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
    Moe SM; Wetherill L; Decker BS; Lai D; Abdalla S; Long J; Vatta M; Foroud TM; Chertow GM
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1128-1138. PubMed ID: 28630081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study.
    St Peter WL; Yusuf AA; Do T; Lowe KA; Liu J; Nieman KM; Bradbury BD; Collins AJ
    BMC Nephrol; 2015 Mar; 16():41. PubMed ID: 25886282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
    Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA
    BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management?
    Turenne MN; Cope EL; Porenta S; Mukhopadhyay P; Fuller DS; Pearson JM; Dahlerus C; Lantz B; Tentori F; Robinson BM
    J Am Soc Nephrol; 2015 Mar; 26(3):754-64. PubMed ID: 25300289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
    Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
    Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Fuller DS; Robinson BM
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):190-199. PubMed ID: 28062678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
    Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
    PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dialysis facility and patient characteristics associated with utilization of home dialysis.
    Walker DR; Inglese GW; Sloand JA; Just PM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1649-54. PubMed ID: 20634324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System.
    Brady BM; Zhao B; Niu J; Winkelmayer WC; Milstein A; Chertow GM; Erickson KF
    JAMA Intern Med; 2018 Oct; 178(10):1358-1367. PubMed ID: 30208398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries.
    Fuller DS; Hallett D; Dluzniewski PJ; Fouqueray B; Jadoul M; Morgenstern H; Port FK; Tentori F; Pisoni RL
    BMC Nephrol; 2019 May; 20(1):169. PubMed ID: 31088377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
    Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
    Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.